Peptidoglycan hydrolases-potential weapons against Staphylococcus aureus
暂无分享,去创建一个
R. Kotłowski | S. Milewski | Piotr Szweda | Roman Kotlowski | Magdalena Zalewska | Marta Schielmann | Grzegorz Gorczyca | Slawomir Milewski | P. Szweda | G. Gorczyca | M. Zalewska | Marta Schielmann
[1] C. Hill,et al. The truncated phage lysin CHAPk eliminates Staphylococcus aureus in the nares of mice , 2010, Bioengineered bugs.
[2] E. Oldham,et al. Lysostaphin: use of a recombinant bactericidal enzyme as a mastitis therapeutic. , 1991, Journal of dairy science.
[3] M. Bochtler,et al. Crystal structures of active LytM. , 2005, Journal of molecular biology.
[4] Vincent A. Fischetti,et al. Gram-positive pathogens , 2006 .
[5] J. Fink-Gremmels,et al. Extended antimicrobial susceptibility assay for Staphylococcus aureus isolates from bovine mastitis growing in biofilms. , 2007, Veterinary microbiology.
[6] J. Suárez,et al. Prevalence of bacteriophages infecting Staphylococcus aureus in dairy samples and their potential as biocontrol agents. , 2009, Journal of dairy science.
[7] I. Wang,et al. Holins: the protein clocks of bacteriophage infections. , 2000, Annual review of microbiology.
[8] David L. Smith,et al. Hospitalizations and Deaths Caused by Methicillin-Resistant Staphylococcus aureus, United States, 1999–2005 , 2007, Emerging infectious diseases.
[9] Julie A. Wu,et al. Lysostaphin Disrupts Staphylococcus aureus and Staphylococcus epidermidis Biofilms on Artificial Surfaces , 2003, Antimicrobial Agents and Chemotherapy.
[10] F. Götz,et al. Evidence for autolysin‐mediated primary attachment of Staphylococcus epidermidis to a polystyrene surface , 1997, Molecular microbiology.
[11] G. Shockman,et al. Chapter 7 Microbial peptidoglycan (murein) hydrolases , 1994 .
[12] D. Ohman,et al. Staphylolysin is an effective therapeutic agent for Staphylococcus aureus experimental keratitis , 2012, Graefe's Archive for Clinical and Experimental Ophthalmology.
[13] D. Patel,et al. Staphylococcal superantigen super-domains in immune evasion. , 2010, Critical reviews in immunology.
[14] B. Martínez,et al. Synergy between the phage endolysin LysH5 and nisin to kill Staphylococcus aureus in pasteurized milk. , 2010, International journal of food microbiology.
[15] A. Coffey,et al. Recombinant bacteriophage lysins as antibacterials , 2010, Bioengineered bugs.
[16] P. M. Pereira,et al. Teichoic acids are temporal and spatial regulators of peptidoglycan cross-linking in Staphylococcus aureus , 2010, Proceedings of the National Academy of Sciences.
[17] J. Costerton,et al. Bacterial biofilms: a common cause of persistent infections. , 1999, Science.
[18] F. Lowy. Antimicrobial resistance: the example of Staphylococcus aureus. , 2003, The Journal of clinical investigation.
[19] M. Bartoszcze,et al. Characterization of a bacteriophage, isolated from a cow with mastitis, that is lytic against Staphylococcus aureus strains , 2011, Archives of Virology.
[20] M. Paape,et al. Genetically enhanced cows resist intramammary Staphylococcus aureus infection , 2005, Nature Biotechnology.
[21] W. Kloos,et al. Identification of "Staphylococcus staphylolyticus" NRRL B-2628 as a Biovar of Staphylococcus simulans , 1982 .
[22] P. Blackburn,et al. In vitro activity of recombinant lysostaphin-antibiotic combinations toward methicillin-resistant Staphylococcus aureus. , 1993, Diagnostic microbiology and infectious disease.
[23] F. Götz,et al. The Presence of Peptidoglycan O-Acetyltransferase in Various Staphylococcal Species Correlates with Lysozyme Resistance and Pathogenicity , 2006, Infection and Immunity.
[24] W. Grubb,et al. Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia. , 1993, The Journal of hospital infection.
[25] J. Rossi,et al. Effect of Enrichment Procedure upon Auxotroph Recovery in Escherichia coli K-12 , 1975, Antimicrobial Agents and Chemotherapy.
[26] F. Götz,et al. The molecular organization of the lysostaphin gene and its sequences repeated in tandem , 1987, Molecular and General Genetics MGG.
[27] R. Kane,et al. Lysostaphin-functionalized cellulose fibers with antistaphylococcal activity for wound healing applications. , 2011, Biomaterials.
[28] K. LaPlante. In vitro activity of lysostaphin, mupirocin, and tea tree oil against clinical methicillin-resistant Staphylococcus aureus. , 2007, Diagnostic microbiology and infectious disease.
[29] V. Fischetti,et al. Bacteriophage lysins as effective antibacterials. , 2008, Current opinion in microbiology.
[30] W. Han,et al. LysGH15 reduces the inflammation caused by lethal methicillin-resistant Staphylococcus aureus infection in mice , 2011, Bioengineered bugs.
[31] B. Martínez,et al. Lytic activity of the virion-associated peptidoglycan hydrolase HydH5 of Staphylococcus aureus bacteriophage vB_SauS-phiIPLA88 , 2011, BMC Microbiology.
[32] S. Walsh,et al. Lysostaphin Cream Eradicates Staphylococcus aureus Nasal Colonization in a Cotton Rat Model , 2003, Antimicrobial Agents and Chemotherapy.
[33] G. Archer,et al. Lysostaphin Treatment of Experimental Methicillin-Resistant Staphylococcus aureus Aortic Valve Endocarditis , 1998, Antimicrobial Agents and Chemotherapy.
[34] D. Ohman,et al. Evaluation of Pseudomonas aeruginosa staphylolysin (LasA protease) in the treatment of methicillin-resistant Staphylococcus aureus endophthalmitis in a rat model , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.
[35] Hume,et al. Lysostaphin treatment of methicillin-resistant staphylococcus aureus keratitis in the rabbit(1) , 2000, American journal of ophthalmology.
[36] W. Hammes,et al. Cloning and expression of the lysostaphin gene in Bacillus subtilis and Lactobadllus casei , 1992 .
[37] J. Fink-Gremmels,et al. Comparative assessment of the antimicrobial susceptibility of Staphylococcus aureus isolates from bovine mastitis in biofilm versus planktonic culture. , 2006, Journal of veterinary medicine. B, Infectious diseases and veterinary public health.
[38] Y. Prasad,et al. Efficacy of Polyvalent Bacteriophage P-27/HP to Control Multidrug Resistant Staphylococcus aureus Associated with Human Infections , 2010, Current Microbiology.
[39] C. Schindler,et al. LYSOSTAPHIN: A NEW BACTERIOLYTIC AGENT FOR THE STAPHYLOCOCCUS. , 1964, Proceedings of the National Academy of Sciences of the United States of America.
[40] Ravi S Kane,et al. Antistaphylococcal nanocomposite films based on enzyme-nanotube conjugates. , 2010, ACS nano.
[41] R. Daum,et al. Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate. , 2001, The Journal of antimicrobial chemotherapy.
[42] Guodong Li,et al. Extension of nasal anti-Staphylococcus aureus efficacy of lysostaphin by its incorporation into a chitosan-o/w cream , 2010, Drug delivery.
[43] F. Milder,et al. Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications , 2010, Journal of Molecular Medicine.
[44] J. Robinson,et al. Relationship between lysostaphin endopeptidase production and cell wall composition in Staphylococcus staphylolyticus , 1979, Journal of bacteriology.
[45] D. Rubin,et al. Methicillin resistant staphylococci. , 1971, JAMA.
[46] K. Honke,et al. Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage phi MR11. , 2007, The Journal of infectious diseases.
[47] J. Kur,et al. New effective sources of the Staphylococcus simulans lysostaphin. , 2005, Journal of biotechnology.
[48] W. Xu,et al. LysGH15, a Novel Bacteriophage Lysin, Protects a Murine Bacteremia Model Efficiently against Lethal Methicillin-Resistant Staphylococcus aureus Infection , 2010, Journal of Clinical Microbiology.
[49] R. O'Callaghan,et al. Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit. , 2002, Investigative ophthalmology & visual science.
[50] F. Haesebrouck,et al. Methicillin-resistant Staphylococcus aureus (MRSA) in food production animals , 2010, Epidemiology and Infection.
[51] R. Sessions,et al. Crystal structure of the LasA virulence factor from Pseudomonas aeruginosa: substrate specificity and mechanism of M23 metallopeptidases. , 2010, Journal of molecular biology.
[52] Paul D. R. Johnson,et al. Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications , 2010, Clinical Microbiology Reviews.
[53] A. Coffey,et al. Characterization of the staphylococcal bacteriophage lysin CHAPK , 2011, Journal of applied microbiology.
[54] D. Ohman,et al. Pseudomonas aeruginosa LasA Protease in Treatment of Experimental Staphylococcal Keratitis , 2004, Antimicrobial Agents and Chemotherapy.
[55] A. Tomasz,et al. Perturbation of Cell Wall Synthesis Suppresses Autolysis in Staphylococcus aureus: Evidence for Coregulation of Cell Wall Synthetic and Hydrolytic Enzymes , 2007, Journal of bacteriology.
[56] Henry F. Chambers,et al. Waves of resistance: Staphylococcus aureus in the antibiotic era , 2009, Nature Reviews Microbiology.
[57] Jan Borysowski,et al. Bacteriophage Endolysins as a Novel Class of Antibacterial Agents , 2006, Experimental biology and medicine.
[58] S. G. Odintsov,et al. Latent LytM at 1.3A resolution. , 2004, Journal of molecular biology.
[59] Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus — Minnesota and North Dakota, 1997-1999. , 1999, MMWR. Morbidity and mortality weekly report.
[60] W. Lane. METHICILLIN RESISTANCE IN STAPHYLOCOCCI , 1962, The Medical journal of Australia.
[61] G. Pier,et al. Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence , 2001, Nature.
[62] Chad W. Euler,et al. Synergism between a Novel Chimeric Lysin and Oxacillin Protects against Infection by Methicillin-Resistant Staphylococcus aureus , 2010, Antimicrobial Agents and Chemotherapy.
[63] J. Saulnier,et al. Hydrolysis of glycine-containing elastin pentapeptides by LasA, a metalloelastase from Pseudomonas aeruginosa. , 2001, European journal of biochemistry.
[64] E. T. Çetin,et al. Staphylococci Resistant to Methicillin (“Celbenin”) , 1962 .
[65] John D. Lambris,et al. Complement evasion by human pathogens , 2008, Nature Reviews Microbiology.
[66] D. Missiakas,et al. Staphylococcus aureus Mutants with Increased Lysostaphin Resistance , 2006, Journal of bacteriology.
[67] Anil Kumar Singh,et al. Identification and characterization of a vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia). , 2008, Journal of medical microbiology.
[68] A. Tomasz,et al. A Staphylococcus aureus autolysin that has an N-acetylmuramoyl-L-alanine amidase domain and an endo-beta-N-acetylglucosaminidase domain: cloning, sequence analysis, and characterization. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[69] S. Taiwo. Methicillin resistance in Staphylococcus aureus: a review of the molecular epidemiology, clinical significance and laboratory detection methods. , 2010, West African journal of medicine.
[70] R. Mecham,et al. Binding and degradation of elastin by the staphylolytic enzyme lysostaphin. , 1995, International Journal of Biochemistry and Cell Biology.
[71] D. Gutiérrez,et al. Lytic Activity of LysH5 Endolysin Secreted by Lactococcus lactis Using the Secretion Signal Sequence of Bacteriocin Lcn972 , 2012, Applied and Environmental Microbiology.
[72] E. Smid,et al. Industrial-scale production and purification of a heterologous protein in Lactococcus lactis using the nisin-controlled gene expression system NICE: The case of lysostaphin , 2005, Microbial cell factories.
[73] U. Bläsi,et al. Holins: form and function in bacteriophage lysis. , 1995, FEMS microbiology reviews.
[74] F. Tenover,et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. , 1997, The Journal of antimicrobial chemotherapy.
[75] W. Schröder,et al. Site-Specific Serine Incorporation by Lif and Epr into Positions 3 and 5 of the Staphylococcal Peptidoglycan Interpeptide Bridge , 2000, Journal of bacteriology.
[76] A. Carnicero,et al. Purification and peptidase activity of a bacteriolytic extracellular enzyme from Pseudomonas aeruginosa. , 1989, Research in microbiology.
[77] J. Borowski,et al. Methicillin-resistant Staphylococci , 1964, Lancet.
[78] Ry Young,et al. The Pinholin of Lambdoid Phage 21: Control of Lysis by Membrane Depolarization , 2007, Journal of bacteriology.
[79] C. Michiels,et al. Food applications of bacterial cell wall hydrolases. , 2011, Current opinion in biotechnology.
[80] Yun-Jaie Choi,et al. Comparison of the Antibacterial Properties of Phage Endolysins SAL-1 and LysK , 2011, Antimicrobial Agents and Chemotherapy.
[81] M. Artenstein,et al. Systemic lysostaphin in man--apparent antimicrobial activity in a neutropenic patient. , 1974, The New England journal of medicine.
[82] L. Heath,et al. The lysostaphin endopeptidase resistance gene (epr) specifies modification of peptidoglycan cross bridges in Staphylococcus simulans and Staphylococcus aureus , 1995, Applied and environmental microbiology.
[83] M. Marquart,et al. The Effectiveness of Lysostaphin Therapy for Experimental Coagulase-Negative Staphylococcus Endophthalmitis , 2006, Current eye research.
[84] W. Hryniewicz,et al. Staphylococcus aureus biofilm as a target for single or repeated doses of oxacillin, vancomycin, linezolid and/or lysostaphin , 2008, Folia Microbiologica.
[85] D. Donovan,et al. Lysis of staphylococcal mastitis pathogens by bacteriophage phi11 endolysin. , 2006, FEMS microbiology letters.
[86] G. Shockman. Microbial peptidoglycan (murein) hydrolases , 1994 .
[87] M. Grinholc,et al. Alternative therapies in Staphylococcus aureus diseases. , 2012, Acta biochimica Polonica.
[88] P. Coote,et al. Bactericidal synergy of lysostaphin in combination with antimicrobial peptides , 2011, European Journal of Clinical Microbiology & Infectious Diseases.
[89] A. Clarke,et al. O-acetylated peptidoglycan: its occurrence, pathobiological significance, and biosynthesis. , 1992, Canadian journal of microbiology.
[90] G. Doern,et al. The Clinical Predictive Value (or Lack Thereof) of the Results of In Vitro Antimicrobial Susceptibility Tests , 2011, Journal of Clinical Microbiology.
[91] D. Donovan,et al. LysK CHAP endopeptidase domain is required for lysis of live staphylococcal cells. , 2009, FEMS microbiology letters.
[92] M. Sugai,et al. Purification and molecular characterization of glycylglycine endopeptidase produced by Staphylococcus capitis EPK1 , 1997, Journal of bacteriology.
[93] D. Ohman,et al. Secreted LasA of Pseudomonas aeruginosa is a staphylolytic protease. , 1993, The Journal of biological chemistry.
[94] R. Jayaswal,et al. Molecular cloning, sequencing, and expression of lytM, a unique autolytic gene of Staphylococcus aureus , 1997, Journal of bacteriology.
[95] B. Martínez,et al. Lytic activity of the recombinant staphylococcal bacteriophage PhiH5 endolysin active against Staphylococcus aureus in milk. , 2008, International journal of food microbiology.
[96] B. Heniford,et al. The addition of lysostaphin dramatically improves survival, protects porcine biomesh from infection, and improves graft tensile shear strength. , 2011, The Journal of surgical research.
[97] S. Walsh,et al. Improved Pharmacokinetics and Reduced Antibody Reactivity of Lysostaphin Conjugated to Polyethylene Glycol , 2003, Antimicrobial Agents and Chemotherapy.
[98] A. Goglio,et al. Methicillin-resistant Staphylococcus aureus: related infections and antibiotic resistance. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[99] Aidan Coffey,et al. Phage Lysin LysK Can Be Truncated to Its CHAP Domain and Retain Lytic Activity against Live Antibiotic-Resistant Staphylococci , 2008, Applied and Environmental Microbiology.
[100] E. Hume,et al. Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit. , 2000, Investigative ophthalmology & visual science.
[101] G. Ayliffe. The progressive international spread of methicillin-resistant Staphylococcus aureus , 1997 .
[102] W. Schaffner,et al. Efficacy and safety of topical lysostaphin treatment of persistent nasal carriage of Staphylococcus aureus. , 1971, Applied microbiology.
[103] J. Leiva,et al. Antibiotic susceptibility assay for Staphylococcus aureus in biofilms developed in vitro. , 1999, The Journal of antimicrobial chemotherapy.
[104] W. Zygmunt,et al. Lysostaphin: model for a specific enzymatic approach to infectious disease. , 1972, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.
[105] D. Ohman,et al. A continuous spectrophotometric assay for Pseudomonas aeruginosa LasA protease (staphylolysin) using a two-stage enzymatic reaction. , 2004, Analytical biochemistry.
[106] A. Friedrich,et al. In Vitro Activity against Staphylococcus aureus of a Novel Antimicrobial Agent, PRF-119, a Recombinant Chimeric Bacteriophage Endolysin , 2011, Antimicrobial Agents and Chemotherapy.
[107] W. Hammes,et al. Stable Expression of the Lysostaphin Gene in Meat Lactobacilli by Introducing Deletions within the Prosequence , 1996 .
[108] J. Weese,et al. Methicillin-resistant Staphylococcus aureus and Staphylococcus pseudintermedius in veterinary medicine. , 2010, Veterinary microbiology.
[109] K. Plaut,et al. Lysostaphin expression in mammary glands confers protection against staphylococcal infection in transgenic mice , 2001, Nature Biotechnology.
[110] G. Ayliffe. The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[111] D. Ohman,et al. Elastase and the LasA Protease of Pseudomonas aeruginosa Are Secreted with Their Propeptides* , 1998, The Journal of Biological Chemistry.
[112] Y. Prasad,et al. P-27/HP Endolysin as Antibacterial Agent for Antibiotic Resistant Staphylococcus aureus of Human Infections , 2011, Current Microbiology.
[113] Wang Di,et al. Trichoderma spp. from rhizosphere soil and their antagonism against Fusarium sambucinum , 2012 .
[114] F. Götz,et al. Activity of the major staphylococcal autolysin Atl. , 2006, FEMS microbiology letters.
[115] D. Ohman,et al. A substitution at His-120 in the LasA protease of Pseudomonas aeruginosa blocks enzymatic activity without affecting propeptide processing or extracellular secretion , 1996, Journal of bacteriology.
[116] Gabriele Bierbaum,et al. Lytic Activity of Recombinant Bacteriophage φ11 and φ12 Endolysins on Whole Cells and Biofilms of Staphylococcus aureus , 2006, Applied and Environmental Microbiology.
[117] D. Missiakas,et al. Recurrent infections and immune evasion strategies of Staphylococcus aureus. , 2012, Current opinion in microbiology.
[118] N. Klyachko,et al. LysK, the enzyme lysing Staphylococcus aureus cells: specific kinetic features and approaches towards stabilization. , 2010, Biochimie.
[119] P. A. Schad,et al. Nucleotide sequence and expression in Escherichia coli of the Pseudomonas aeruginosa lasA gene , 1988, Journal of bacteriology.
[120] C. Schindler,et al. PURIFICATION AND PROPERTIES OF LYSOSTAPHIN--A LYTIC AGENT FOR STAPHYLOCOCCUS AUREUS. , 1965, Biochimica et biophysica acta.
[121] Chad W. Euler,et al. A Novel Chimeric Lysin Shows Superiority to Mupirocin for Skin Decolonization of Methicillin-Resistant and -Sensitive Staphylococcus aureus Strains , 2010, Antimicrobial Agents and Chemotherapy.
[122] A. Loeffler,et al. Companion animals: a reservoir for methicillin-resistant Staphylococcus aureus in the community? , 2010, Epidemiology and Infection.
[123] A. Pande,et al. Cytoplasmic expression of mature glycylglycine endopeptidase lysostaphin with an amino terminal hexa-histidine in a soluble and catalytically active form in Escherichia coli. , 2006, Protein expression and purification.
[124] K. Schleifer,et al. Peptidoglycan Types of Bacterial Cell Walls and Their Taxonomic Implications , 1973, Bacteriological reviews.
[125] U. Bläsi,et al. Phage P68 Virion-Associated Protein 17 Displays Activity against Clinical Isolates of Staphylococcus aureus , 2005, Antimicrobial Agents and Chemotherapy.
[126] P. Courvalin,et al. VanA-Type Vancomycin-Resistant Staphylococcus aureus , 2009, Antimicrobial Agents and Chemotherapy.
[127] G. Fitzgerald,et al. The Recombinant Phage Lysin LysK Has a Broad Spectrum of Lytic Activity against Clinically Relevant Staphylococci, Including Methicillin-Resistant Staphylococcus aureus , 2005, Journal of bacteriology.
[128] S. Shahsavan,et al. Emergence of High-Level Vancomycin-Resistant Staphylococcus aureus in the Imam Khomeini Hospital in Tehran , 2008, Medical Principles and Practice.
[129] W. Vollmer,et al. Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan O‐acetyltransferase OatA is the major determinant for lysozyme resistance of Staphylococcus aureus , 2004, Molecular microbiology.
[130] I. Lasa,et al. Lysostaphin and clarithromycin: a promising combination for the eradication of Staphylococcus aureus biofilms. , 2011, International journal of antimicrobial agents.
[131] M. Loessner,et al. Bacteriophage endolysins--current state of research and applications. , 2005, Current opinion in microbiology.
[132] J. Mond,et al. Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice. , 2009, The Journal of antimicrobial chemotherapy.
[133] E. Smid,et al. Optimization of the Lactococcus lactis nisin-controlled gene expression system NICE for industrial applications , 2005, Microbial cell factories.
[134] G. Archer,et al. Lysostaphin Treatment of Experimental Aortic Valve Endocarditis Caused by a Staphylococcus aureus Isolate with Reduced Susceptibility to Vancomycin , 1999, Antimicrobial Agents and Chemotherapy.
[135] M. Bochtler,et al. Anti-staphylococcal activities of lysostaphin and LytM catalytic domain , 2012, BMC Microbiology.
[136] J. Synowiecki,et al. PROTECTIVE EFFECT OF LYSOSTAPHIN FROM STAPHYLOCOCCUS SIMULANS AGAINST GROWTH OF STAPHYLOCOCCUS AUREUS IN MILK AND SOME OTHER FOOD PRODUCTS , 2007 .
[137] F. Götz,et al. Studies on prolysostaphin processing and characterization of the lysostaphin immunity factor (Lif) of Staphylococcus simulans biovar staphylolyticus , 1997, Molecular microbiology.
[138] A. Tomasz,et al. Altered muropeptide composition in Staphylococcus aureus strains with an inactivated femA locus , 1993, Journal of bacteriology.
[139] O. Iversen,et al. Studies on lysostaphin. Separation and characterization of three enzymes. , 1973, European journal of biochemistry.
[140] G. Archer,et al. Combinations of Lysostaphin with β-Lactams Are Synergistic against Oxacillin-Resistant Staphylococcus epidermidis , 2002, Antimicrobial Agents and Chemotherapy.
[141] C. Weidenmaier,et al. Influence of Wall Teichoic Acid on Lysozyme Resistance in Staphylococcus aureus , 2006, Journal of bacteriology.
[142] W. Hryniewicz,et al. Lysostaphin as a potential therapeutic agent for staphylococcal biofilm eradication. , 2005, Polish journal of microbiology.
[143] R. Jayaswal,et al. Characterization of a chromosomally encoded glycylglycine endopeptidase of Staphylococcus aureus. , 1999, Microbiology.